IL-13 mRNA tissue content identifies two subsets of adult ulcerative colitis patients with different clinical and mucosa-associated microbiota profiles by Butera, Alessia et al.
Ac
ce
pte
d M
an
us
cri
pt
Manuscript Doi: 10.1093/ecco-jcc/jjz154 
Copyright © 2019 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All 
rights reserved. For permissions, please email: journals.permissions@oup.com 
IL-13 mRNA tissue content identifies two subsets of adult ulcerative colitis patients 
with different clinical and mucosa-associated microbiota profiles 
Alessia Butera1, Monica Di Paola2, Francesco Vitali3, Daniela De Nitto4, Francesco Covotta5, 
Francesco Borrini6, Roberta Pica4, Carlotta De Filippo3, Duccio Cavalieri2, Alessandro Giuliani7§, 
Annamaria Pronio5§, Monica Boirivant1§ 
1 Istituto Superiore di Sanità, National Center for Drug Research and Evaluation, Rome, Italy, 2 
Department of Biology, University of Florence, Firenze, Italy, 3Institute of Agricultural Biology and 
Biotechnology, National Research Council, Pisa, Italy, 4Sandro Pertini Hospital, IBD, GE Unit, Rome, 
Italy, 5University “Sapienza”, Dept General Surgery, “P. Stefanini”, Rome, Italy, 6Sandro Pertini 
Hospital, UOC Pathology Section, Rome, Italy, 7Istituto Superiore di Sanità, Dept Environment and 
Health, Rome, Italy    
§ Authors share co-senior authorship. 
Contact details: Alessia Butera: alessia.butera@iss.it, Monica Di Paola: monica.dipaola@unifi.it, 
Francesco Vitali: francesco.vitali.bio@gmail.com, Daniela De Nitto: denittod@hotmail.com, 
Francesco Covotta: francesco.covotta@gmail.com, Francesco Borrini: francesco.borrini@aslroma2.it, 
Roberta Pica: roberta.pica@aslroma2.it, Carlotta De Filippo: carlotta.defilippo@ibba.cnr.it, Duccio 
Cavalieri: duccio.cavalieri@unifi.it, Alessandro Giuliani: alessandro.giuliani@iss.it, Annamaria 
Pronio: annamaria.pronio@uniroma1.it 
Corresponding Author: 
Monica Boirivant, MD 
National Center for Drug Research and Evaluation 
Istituto Superiore di Sanità 
Viale R. Elena, 299 
00161 Roma 
ITALY 
Phone:+390649902976 
e-mail:  
 
This study was presented in part to the DDW 2018 Washington DC. USA 
  
D
ow
nloaded from
 https://academ
ic.oup.com
/ecco-jcc/advance-article-abstract/doi/10.1093/ecco-jcc/jjz154/5566583 by guest on 11 Septem
ber 2019
Ac
ce
pte
d M
an
us
cri
pt
Manuscript Doi: 10.1093/ecco-jcc/jjz154 
 
ABSTRACT 
 
Background and Aim. A personalized approach to therapy has great promise to improve disease 
outcomes. To this end, the identification of different subsets of patients according with the prevalent 
pathogenic process might guide in the choice of therapeutic strategy. We hypothesize that UC patients 
might be stratified according to distinctive cytokine profiles and/or to a specific mucosa-associated 
microbiota Methods. In a cohort of clinically and endoscopic active UC patients and controls, we 
analyzed by qPCR the mucosal cytokine mRNA content and the mucosa-associated microbiota 
composition assessed by the 16SrRNA gene sequencing. Results. We demonstrate, by means of data-
driven approach, the existence of a specific UC patient subgroup characterized by elevated IL-
13mRNA tissue content separated by patients with low IL-13 mRNA tissue content. The two subsets 
differ in clinical-pathological characteristics. High IL-13mRNA patients are younger at diagnosis and 
show higher prevalence of extensive colitis than low IL-13mRNA ones. They also show a more 
frequent use of steroid/immunosuppressant/anti-TNF therapy during a one-year follow-up. The two 
subgroups show a differential enrichment of mucosa associated microbiota genera with prevalence of 
Prevotella in patients with high IL-13mRNA tissue content and Sutterella and Acidaminococcus in 
patients with low IL-13mRNA tissue content. Conclusion. Assessment of mucosal IL-13mRNA might 
help in the identification of the patients’ subgroup that might benefit from a therapeutic approach 
modulating IL-13.  
Keywords: Ulcerative colitis, IL-13, microbiota 
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INTRODUCTION 
 
A personalized approach to therapy has great promise to improve disease outcomes. Selection of 
patients as candidates for the early introduction of highly effective therapy can both maximize 
treatment efficiency and prevent long-term complications. The classic pro-inflammatory cytokines 
(such as IL-6 and TNF-) have an accepted role in the pathogenesis of inflammatory lesions, and 
recent findings showed that Th17 response also participates in the inflammatory process (1, 2). 
Ulcerative Colitis (UC) has been associated with an atypical Th2 cell response mediated inflammation 
(3-6). Although some evidences provided a proof of concept that IL-13 is an effector cytokine in UC (7), 
administration of anti-human IL-13 neutralizing monoclonal antibody, did not significantly improve 
clinical response vs placebo in UC patients (8). However, in the same study, the proportion of patients 
who achieved clinical remission was statistically significantly higher in the anti-IL-13 treated group 
compared with the placebo group (8), suggesting the presence of a UC patients' subgroup responding to 
IL-13 neutralizing treatment. 
It is increasingly evident that there is a close relationship between the microbiota composition and gut 
immune response, which includes both the cellular and the soluble component of the immune response. 
Specific components of the gut microbiota are involved in the production of pro-inflammatory 
cytokines and subsequent generation of Th17 cells (9, 10). Similarly, commensal bacteria and their 
metabolites can also promote the generation of regulatory T cells (10-13) which, in turn, influence the 
microbiota composition (14). 
We hypothesize that UC patients might be stratified according to distinctive cytokine profiles and/or to 
a specific mucosa-associated microbiota. Therefore, we analyzed the mucosal cytokine mRNA content 
and the mucosa-associated microbiota composition of a cohort of clinically and endoscopic active UC 
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patients. We demonstrate, by means of data-driven approach, in the context of a generalized increased 
mRNA IL-17A tissue content in UC patients, the existence of a specific UC patient subgroup 
characterized by elevated IL-13 mRNA tissue levels distinct by patients with IL-13 mRNA levels not 
distinguishable by control subjects. Furthermore, the two patients’ subgroups (high and low IL-
13mRNA tissue content) show different clinical-pathological characteristics and a differential 
enrichment of mucosa-associated microbiota genera known to be involved in UC dysbiosis. 
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METHODS 
 
Patients. A total of 88 UC patients attending two clinical tertiary centers (IBD, GE Unit, Sandro 
Pertini Hospital, Rome, and Department of General Surgery, “P. Stefanini", Sapienza University, 
Rome) with endoscopically active disease (Mayo score ≥1 (15)) were evaluated. All the patients were not 
on rectal 5-ASA and/or steroids in the last 3 months, nor had assumed antibiotics in the last 3 months. 
A control group of 24 subjects undergoing colonoscopy for colon cancer screening or suspected 
functional bowel disorders was also included. In UC patients, disease extension, at the time of 
endoscopy, was classified using the Montreal classification (16) as follows: proctitis, involvement 
limited to the rectum; left-sided colitis, involvement limited to a portion of the colorectum distal to the 
splenic flexure; extensive colitis, involvement extending proximal to the splenic flexure. Multiple 
endoscopic mucosal biopsies were obtained from endoscopically involved and uninvolved areas in UC 
patients, and from matched areas in controls. Histopathology was quantified in H&E stained tissue 
sections using the Robarts histopathology index (RHI) (17). RHI values <3 and >6 were recorded for all 
biopsy samples collected from uninvolved and involved tissue, respectively. Histology confirmed the 
absence of inflammatory changes in controls. For cytokine/microbiota analysis, multiple biopsies taken 
from involved and uninvolved tissue were stored in RNA later for quantification of cytokine profile 
and identification of mucosa-associated microbiota by metagenomics analysis. Biopsies samples for 
RNA extraction were available in 81 UC patients and 21 Controls. 20 controls and 77 patients (77 
samples from involved tissue and 50 samples from uninvolved tissue within the same patients) gave 
rise to a good quality RNA to be amplified. Biopsies for microbiota analysis were available in 24 
controls and 88 UC patients. 21 controls and 79 patients (79 samples from involved tissue and 57 
samples from uninvolved tissue within the same patients) endowed with a sufficient quality data for 
sequencing analysis. In 68 patients both RNA and microbiota analysis were available.  
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Clinical-pathological variables of patients contributing cytokine, microbiota or cytokine+ microbiota 
data were largely superimposable. Given the main focus of the study is on the immunological 
subtyping we report the clinical-pathological variables for the 77 patients data set (Table1). 
Cytokine tissue mRNA content quantification 
RNA was extracted using RNA mini Kit Plus (Qiagen, Hilden, Germany) and its quality analyzed by 
Agilent RNA 6000 Nano Kit using Agilent 2100 Bioanalyzer instrument (Agilent Technologies, Santa 
Clara, CA). RNA with Refractive Index Detector (RID) ≥ 7 was used for subsequent analysis. cDNA 
was reverse transcribed from 1g of RNA using the High-Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems™ - Thermo Fisher Scientific, Massachusetts, USA). We quantified by 
quantitative real-time PCR (RTqPCR) the tissue content of TNF-α, IL-6, IFN-γ, IL-17A, IL-10 and IL-
13 using the following primers: TNF-α forward 5-CCCAGGGACCTCTCTCTAATCA, reverse 5-
GCTACAGGCTTGTCACTCGG-3; IL-6 forward 5’-CCACTCACCTCTTCAGAACG-3’, reverse 5’-
GCCTCTTTGCTGCTTTCACAC-3’; IFN-γ - forward: 5’-ATAGGTAACTGACTTGAATGTCCA-3’, 
reverse 5’-GCTCTTCGACCTCGAAACAGC-3’; IL-17A - forward: 5’-
ACTACAACCGATCCACCTCAC-3’, reverse 5’-ACTTTGCCTCCCAGATCACAG-3’; IL-10-
forward 5’-CCCAAGCTGAGAACCAAGACC-3’, reverse 5’-TCACAGGGAAGAAATCGATGAC-
3’; IL-13 - commercially available primers RT² qPCR Primers Assay (Qiagen) cat.PPH00688FRPS. As 
housekeeping gene, we utilized RPS9 –forward: 5’-AAGCTGATCGGCGAGTATG-3’, reverse 5’-
TCTTCAGGCCCAGGATGTAA-3’ (18). The gene amplification was performed in duplicate at Tm-
60°C using Fast SYBR™ Green Master Mix (Applied Biosystems™ - Thermo Fisher Scientific). Data 
are expressed as Log2 (Relative Expression) coming from the equation: Relative Expression = 40-DCt 
where 40 is the maximum number of cycles and DCt is the difference in number of cycles of the gene 
of interest with the housekeeping gene. We attributed a relative expression of 40 to samples with 
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undetectable expression, (threshold cycle ≥ 40); next, we estimated the relative expression as described 
above. 
Statistical analysis 
The presence of a statistically significant difference between controls and UC patients’ cytokine tissue 
mRNA content was assessed by Mann-Whitney’s U. The optimal ‘clustering properties’ of IL-17A and 
IL-13 with respect to the other cytokines were assessed by means of pseudo F statistics (19, 20) 
bimodality index as well as by the correlation structure among a set of cytokines by means of Pearson 
correlation and Principal Component Analysis (PCA). The bi-dimensional space spanned by IL-17A 
and IL-13 was analyzed by K-means (21), the by far most common unsupervised non-hierarchical 
clustering technique   maximizing the Between/Within cluster variance ratio. The choice of the number 
of clusters (K value) was based upon the maximal distance of the observed R-square (Between cluster 
variance/Total variance ratio) with the one expected by a Gaussian distribution of data. The search for 
relevant correlations between cluster composition and clinical-pathological variables was performed by 
means of Chi-Square statistics and Analysis of Variance for categorical and interval variables 
respectively. 
Mucosal samples collection and bacterial genomic DNA extraction 
Endoscopic biopsies were collected in RNAlater and stored at -80°C until extraction of nucleic acids. 
The bacterial genomic DNA extraction was carried out with DNeasy PowerLyzer PowerSoilKit 
(Qiagen, Hilden, Germany) following the manufacturer’s instructions. DNA quality was assessed by 
gel electrophoresis and spectrophotometry, measuring OD 260/280. 
16S Ribosomal RNA Gene Amplicons preparation and Illumina MiSeq sequencing 
Library of 16S rRNA gene amplicons was prepared by IGA Technology Services (Udine, Italy) 
through amplification of the V3-V4 hypervariable region by using specific-barcoded primers with 
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overhang adapters. The standard protocol was followed according to the 16S metagenomic sequencing 
library preparation guide from Illumina (Part # 15044223 Rev. B; https://support.illumina.com/). 
Pooled V3-V4 amplicon libraries were sequenced using the Illumina MiSeq platform. Each sample was 
sequenced at IGA Technology (Udine, Italy) using Illumina MiSeq instrument and a 300-bp paired-end 
reads protocol. 
Sequencing Data analysis 
Demultiplexed reads were downloaded and quality checked using FastQC 0.11.5. Reads were further 
pre-processed by removing Illumina sequencing adaptors with CUTADAPT (22), and by trimming the 
low quality end of each read with SICKLE (23), with a quality threshold of 20. Trimmed forward and 
reverse reads were then joined with PEAR (24) and checked for chimera presence with VSEARCH (25). 
OTUs picking was performed in QIIME 1.8 (26) with uclust algorithm (27) using default values, and 
assigning the taxonomy using the GreenGenes 13.8 database. Low coverage OTUs were filtered using 
filter_otus_from_otu_table.py and parameter --min_count_fraction 0.00005. 
Subsequent analyses were performed in R statistical software. The file produced by QIIME was parsed 
in R with phyloseq package (28) and OTUs count data were normalized by cumulative sum scaling 
(CSS) as implemented in the metagenomeSeq package (29). Alpha diversity was evaluated using 
Observed richness (the number of different OTUs in a sample), Shannon’s diversity Index (a measure 
of community diversity, accounting for both abundance and evenness of bacterial OTUs), and 
Evenness index (a measure of uniformity of relative abundances of the OTUs in a sample) (30). Beta 
diversity was analyzed by means of principal coordinate analysis (PCoA) based on Bray-Curtis 
dissimilarity index producing an explicit metric space from microbiome profiles dissimilarities. 
Inferential statistics on the above described metrics was performed by Analysis of Variance and 
Student’s t-test. LEfSe (Linear discriminant analysis Effect Size) (31) on the CSS transformed 
abundances, was performed to identify plausible bacterial biomarker(s) able to separate different 
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groups. In LEfSe, Kruskal–Wallis rank-sum test (significance threshold 0.05) was firstly used to 
identify significantly different taxa abundances among classes (in this case, we used patients’ clusters 
as group variable), and then LDA (linear discriminant analysis) is used to estimate the size of  the 
discriminating effect for each feature. A feature (i.e. a Genus-level OTU) is retained as a suitable 
biomarker of a class if the LDA value (Between/Within Variance ratio) was higher than 2. 
Microbiota sequence data are available at http://www.ebi.ac.uk, under the accession number 
PRJEB31884. The script used for pre-treatment and OTUs picking, as well as the script for data 
analysis performed in R, are available at the following GitHub repository 
https://github.com/FrancescoVit/Supplementary-to-Butera-et-al.-2019 
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RESULTS 
IL-13 mRNA tissue content allows for a meaningful classification of UC patients  
We preliminary analyzed the mRNA tissue content of different cytokines in UC patients and control 
subjects. As illustrated in Figure 1, in UC patients, all the cytokines evaluated show significantly 
increased mRNA tissue content in the involved tissue vs uninvolved tissue that in turn show values 
comparable to controls. However, it is worth noting IL-13 values have a clear bimodal distribution, 
while IL-17A values in UC involved tissue show the smallest overlap with the controls suggesting 
discriminatory ability in separating the two groups. Analysis of Variance as applied to controls-patients 
discrimination resulted statistically significant for all the analyzed cytokines with the only exception of 
IL-13 (Supplementary Table 1). Moreover, IL-13 distribution and the related quantile-quantile (Q-Q) 
distribution (Supplementary Figure 1, panel A and B, respectively) clearly show a deviation from the 
normal distribution for both patients and controls, thus not related to “a priori class discrimination” 
suggesting clustering relevance of IL-13 for the detection of disease sub-groups. This suggestion had a 
strong proof by the application of two independent computational approaches: a) Bimodality estimation 
by Pseudo F statistics (19, 20) and b) Pearson correlation and Principal Component Analysis as applied to 
cytokine profile of UC patients.  
Pseudo-F statistics corresponds to the ratio of Between/Within cluster variance: the greater this ratio, 
the greater the relevance of the clusters. In the case of two clusters, the Pseudo-F is an index of 
bimodality, with high values pointing to the presence of two distinct populations in the same set. 
We computed the Pseudo-F statistics on the two cluster optimal K-means solution for all the evaluated 
cytokines independently from the control/patient a priori classification. According with this analysis 
IL-17A and IL-13 were the two cytokines endowed with the higher values of the index and thus the two 
optimal variables for classification purposes (Supplementary Table 2). In the case of IL-17A, Pseudo-F 
D
ow
nloaded from
 https://academ
ic.oup.com
/ecco-jcc/advance-article-abstract/doi/10.1093/ecco-jcc/jjz154/5566583 by guest on 11 Septem
ber 2019
Ac
ce
pte
d M
an
us
cri
pt
Manuscript Doi: 10.1093/ecco-jcc/jjz154 
 
registers the control/patient discriminatory power of this cytokine. On the contrary, the lack of any 
control/patient discriminant power of IL-13 makes the elevated Pseudo-F values of this cytokine the 
image in light of a different latent biological categorization. 
Even more compelling, we found that the differences in mRNA tissue content of the involved vs 
uninvolved colonic area from the same patient relative to IL-6, TNF-, IFN- and IL-10 were each 
other strongly correlated (Pearson correlation coefficient), while IL-17A and IL-13 variations were 
both independent from all the other cytokine mRNA concentration and independent of each other. This 
correlation structure gave rise to a three principal components (PCs) solution of the entire cytokine 
space (Supplementary Table 3). The first principal component (PC1, explaining 49% of total variance) 
consists in an aspecific inflammatory response including the joint variation of all the cytokines 
evaluated, with the exception of IL-13 and IL-17A. Notably, IL-13 and IL-17A belong to two mutually 
independent components (PC2 and PC3) explaining 19.4% and 16.5% of total variance respectively. 
The inspection of component loading, correspondent to the Pearson correlation between original 
variable and components (Supplementary Table 3 and accompanying Figure) identifies PC2 with IL-13 
(Pearson r=0.94) and PC3 with IL-17A (Pearson r=0.96) respectively. The above results point to 
additional properties (the com onents are each other orthogonal by construction) of IL-13 and IL-17A 
(PC2 and PC3), independent from aspecific inflammation (PC1) that can be used to identify subgroups 
of UC patients by means of a clustering approach on these two cytokines. Thus, while PC1 is a ‘size’ 
component (32, 33), both PC2 and PC3 are ‘shape’ components independent of the ‘entity’ of 
inflammation (registered by PC1) and potentially useful for the discrimination of disease sub-groups. 
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UC patients are distributed in clusters characterized by high and low IL-13 mRNA 
Given the above described observations, we concentrated on IL-13 and IL-17A mRNA levels in order 
to single out a reliable partition of the data. As shown in Figure 2, the combination of the two cytokines 
indeed clearly separated UC patients from control subjects confirming the significant alteration of the 
two cytokine expression due to the disease. We then evaluated the distribution of subjects in the IL-
17A/IL-13 plane. As shown in Figure 3A only UC patients have IL-17A values greater than the mean 
value of IL-17A (right quadrants), while, as far as IL-13 values, the higher than mean values belong to 
both UC patients and control subjects although the former are prevalent. Thus, distribution of IL-17A 
and IL-13mRNA values points to the existence of discrete clusters of subjects. A k-means cluster 
analysis on the IL-17A/IL-13 plane was computed (Figure 3B). It is worth to stress that k-means is an 
unsupervised technique and does not take into account the class of the subjects (patients or controls) 
but only their mutual relations in the IL-17A/IL-13 plane. Data represented in Supplementary Figure 2 
points to a six clusters partition as optimal. The six clusters partition explains 91% of the total 
information present in the data set (R-square=0.91). With the only exception of cluster 1 
(accommodating for two outlier observations), the classes are sufficiently populated to allow for a 
reliable profiling of IL-17A and IL-13 tissue content. The IL-17A mRNA tissue content varies 
smoothly from healthy to diseased patients: the ‘extreme’ cluster 6 and cluster 2 are devoid of any 
control subject, while the intermediate and ‘left side of the plane’ clusters have a mixed controls/UC 
populations (Figure 3B). Cluster 6 is made of patients with ‘high IL-17A/high IL-13’ pattern, while 
cluster 2 have a ‘high IL-17A/low IL-13’ pattern (Figure 3B). The above analysis allows us to define a 
bipartite profile of UC patients according to ‘high IL-13’ (Cluster 6) and ‘low IL-13’ (Cluster 2) 
mRNA tissue content in the context of high IL-17A mRNA tissue content.  
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Clusters in the IL-13/IL-17A plane show differences as for sex, age at diagnosis, prevalence of 
extensive colitis and steroid/ immunosuppressant/anti-TNF-a therapy use 
Having proved the existence of patient cluster distribution (further confirmed by bootstrap 
simulations), we analyzed the observed cytokine-based patient subgroups according to the clinical-
pathological variables. We preliminary assessed the presence of differences in the clinical--pathological 
variable among the clusters 2, 3 and 4 (low IL-13mRNA content) and between the clusters 5 and 6 
(high IL-13 mRNA content). Since we did not find any statistical differences (Supplementary Table 4) 
we grouped cluster 2, 3 and 4 (low IL-13mRNA content) and cluster 5 and 6 (high IL-13mRNA 
content) for the analysis. No differential distribution as for disease duration (139±20 vs 123±16 
months, mean±SE; p=0.5, low and high IL-13 subset, respectively), therapy at time of endoscopy 
(corticosteroids, immunosuppressant, biological therapy at the time of endoscopy: 33% vs 32 % low 
and high IL-13 subset, respectively) and endoscopic Mayo score (1.9±0.12 vs 2.1±0.11, mean±SE; 
p=0.38, low and high IL-13 subset, respectively), was observed. A significantly lower prevalence of 
females was observed in patients belonging to low IL-13 mRNA tissue content (Figure 4A). Patients 
with high IL-13 mRNA tissue content show a significant lower age at diagnosis than patients with low 
IL-13 mRNA tissue content (Figure 4B). A significant higher prevalence of patients with extensive 
colitis was observed in patients with high IL-13 mRNA than in patients with low IL-13 mRNA tissue 
content (Figure 4C). In 42 out of the 77 patients, information regarding therapy during at least 1 year of 
follow-up was available. This subset of patients did not differ from the whole group as for clinical--
pathological variables at entry (Supplementary Table 3). Furthermore, the distribution along different 
clusters of the 42 patients in which follow up was available did not differ from the whole set 
distribution (clusters 2+3+4: 41.86% vs 42.86%; clusters 5+6: 58.14% vs 57.14%, respectively). 
Therefore, we considered the 42 patients subset as an unbiased subsample of the whole set.  
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In this subset of patients, the relative frequency of clinical relapses during the one-year follow-up 
period did not differ between patients with low and high IL-13mRNA content (27 vs 29 %, proportion 
of patients with clinical relapses, respectively). However, patients with high IL-13 mRNA showed, 
during the follow-up, but not at the time of endoscopy (corticosteroids, immunosuppressant, biological 
therapy: 27.78% vs 20.83% low and high IL-13 subset, respectively), increased steroid/ 
immunosuppressant/anti-TNF-therapy use to reach and maintain the remission, when compared with 
patients with low IL-13mRNA (Figure 4D). Taken together, the above results suggest that UC patients 
showing high IL-13 mRNA tissue content have a more severe colitis than patients showing low IL-13 
mRNA tissue content. 
When males and females were separately analyzed for the clinical-pathological variables described 
above, it appears that the only variable influenced by gender was the age at diagnosis where males 
contributed to the observed significant lower age at diagnosis in patients belonging to clusters 5+6 
(males clusters 5+6: 30 (4-61) vs males clusters 2+3+4: 42 (20-74), median (range); p= 0.0043, by 
Mann Whitney test). 
Characterization of mucosa-associated microbiota in UC patients and controls 
To investigate the ability of microbiota composition to identify different UC patients subsets or to 
complement cytokine profile information, we preliminary evaluated mucosal microbiota composition 
in UC patients (both in involved and uninvolved tissue) and in controls, by performing Illumina MiSeq 
sequencing of 16S rDNA. A summary of microbiota profiles (relative abundances) at family level is 
reported in Figure 5A.  
As for α-diversity (Supplementary Figure 3) and ß-diversity (Figure 5B), we did not observe major 
differences in the mucosa-associated microbial profiles between UC and Controls (both involved and 
uninvolved tissue). Furthermore, we did not observe major differences between involved and 
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uninvolved tissue in UC patients. Interestingly, PCoA performed on Bray-Curtis distances suggests a 
three group’s ordination of mucosa-associated microbial profiles, varying independently from mucosal 
tissue type (involved, uninvolved, control mucosa) (Figure 5B), IL-13 and IL-17 tissue cytokine 
content (Supplementary Figure 4), cytokine clusters (Supplementary Figure 5), as well as clinical-
pathological variables (Supplementary Table 5). 
Considering the data-driven characteristic of PCoA, this implies neither disease, nor cytokine profile 
are relevant order parameters of the microbiota profile. Thus, the global microbiota profile stems from 
other biological features (e.g. diet, micro-environmental features, genetics) and we can only focus on 
local microbial features to try to get a ‘signature’ of the disease and cytokine status. This 
methodologically implies the shift from a data-driven (PCoA) to a supervised (Discriminant Analysis) 
approach. When discriminant microbial signatures were investigated by LEfSe analysis (Figure 5C-D), 
comparison between controls mucosa-associated microbiota (Controls, gray highlighted node of the 
tree) and UC mucosa-associated microbiota (both involved and uninvolved, red node of the tree) 
showed an enrichment of Roseburia genus in control mucosa compared to UC (Figure 5C), as 
previously reported in several studies (34-36). 
UC samples (involved and uninvolved tissue) showed relative enrichment of Bifidobacteriaceae, 
Gemellaceae, Enterococcaceae, Eryspelothricaceae, and Lactobacillales, including also 
Bifidobacterium, Enterococcus and Acidaminococcus genera (Figure 5B). When we examined 
differential taxa between involved mucosa and uninvolved mucosa (Figure 5C), Bifidobacterium and 
Acidaminococcus genera and Gemellaceae family were enriched in uninvolved mucosa, while, 
Lactobacillus, Eubacterium and Enterococcus genera were enriched in the involved mucosa. These 
data are in agreement with the reported increase in UC fecal samples of Enterococcaceae, 
Lactobacillaceae (37) families and Enterococcus genus (38) suggesting that the contribution to the 
reported increase in fecal samples is mainly due to the increase observed in inflamed tissue.  
D
ow
nloaded from
 https://academ
ic.oup.com
/ecco-jcc/advance-article-abstract/doi/10.1093/ecco-jcc/jjz154/5566583 by guest on 11 Septem
ber 2019
Ac
ce
pte
d M
an
us
cri
pt
Manuscript Doi: 10.1093/ecco-jcc/jjz154 
 
Comparative analysis of mucosal microbiota composition in CL6 (high IL-13 tissue content) and CL2 
(low IL-13 tissue content) patients’ clusters 
Mucosal microbiota composition was further analyzed focusing on the subset of involved tissues in 
subjects belonging to cytokine Cluster 6 (CL) and CL 2, the two clusters populated by UC patients only 
characterized by high and low IL-13 mRNA, respectively. Alpha diversity analysis (i.e. richness, 
evenness, Shannon’s index, and Faith’s phylogenetic diversity index; Supplementary Figure 6A) and 
beta diversity (Supplementary Figure 6B) did not highlight differences between involved mucosa-
associated microbiota of patients in CL6 and CL2. Interestingly, when we selected only samples 
belonging to CL6 and CL2 to evaluate their ß-diversity (Supplementary Figure 6B), the spatial 
arrangement of samples on the ordination space (PCoA based on Bray-Curtis distances) resembled the 
one observed in the complete samples population (Figure 5B). This evidence further confirms our 
previous observation that the global microbiota profile stems from other biological features than 
cytokine status alone. 
Nevertheless, when differences between involved mucosa-associated microbiota of patients belonging 
to the two cluster that show the lowest (CL2) and the highest (CL6) IL-13 values were evaluated by 
LEfSe (Figure 6), Prevotella genus resulted a microbial signature associated to subjects in CL6, while 
Acidaminococcus and Sutterella genera, were associated to patients in CL2. 
Interestingly, a more in-depth sequencing analysis at species-level revealed that 2.5% of the total 
number of the reads (218’557 out of 8’498’053 total number) were assigned to Prevotella spp. and 
Prevotella copri was present in more than 50% of the CL6 samples (Supplementary Figure 7). 
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DISCUSSION 
 
In the present study, we demonstrated the existence of two different subsets of adult endoscopically 
active UC patients characterized, in the context of a generalized increase of IL-17A tissue mRNA 
content, by high and low IL-13 tissue mRNA content. Patients in the two subsets show different 
clinical-pathological characteristics and some local microbial markers.  
Among the cytokines explored in the present study, only IL-17A and IL-13 show classificatory ability 
independent from the global inflammatory status of the patients (PC1, see Results). IL-17A and IL-13 
are each other linearly independent, with IL-17A marking the ‘presence of disease’ and IL-13 the 
disease sub-typing.  Our observation of increased IL-17A expression in UC is in line with previous 
observations by our and other groups (2, 7, 39, 40), and with a recent report in which a large cohort of 
pediatric patients was evaluated (41). Notably, in the last reported study, increased IL-17A and IL-13 
mRNA tissue content (with no significant correlation between IL-13 and IL-17A expression) were 
increased in ulcerative colitis and IL-17A and IL-5 mRNA expression were able to distinguish UC 
from colon-only Crohn’s disease (41). It has been recently shown that the ratio of mucosal IL17A to 
IL17F expression correlate significantly with endoscopic disease activity in adult UC (42) and we 
previously demonstrated that dual expression of IL17A by CD4+CD25- regulatory T cells expressing 
surface transforming growth factor- in its latent form (LAP) reduces the suppressor activity of these 
cells in UC (2). In  addition to IL-17A, sufficient evidence points to IL-13 as an important pathological 
factor in adult and pediatric UC patients (3, 4, 41,43, 44), although few reports (45, 46) did not show increased 
level of IL-13 in UC patients. The reason for such discrepancies may reside in both the different 
experimental techniques (45, 46) and the very low number of patients in which IL-13mRNA was 
evaluated (45) in the latter mentioned studies. 
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The two subsets of UC patients observed in the present study differ in the prevalence of gender, being 
females more represented in the high IL-13 subset, as well as in the age at diagnosis that was 
significantly lower in the high IL-13 patients’ subset when compared to the low IL-13 patients’ subset. 
No significant difference between the two subsets in the disease duration from the diagnosis was 
observed.  
As regard disease characteristics, the high IL-13 patients’ subset show an increased prevalence of 
extensive colitis. Furthermore, in the group of 42 patients in which clinical information during the 
follow-up were available, the use of steroids, immunosuppressant and biological agents to achieve and 
maintain clinical remission, not significantly different at the time of endoscopy, was higher in the high 
IL-13 patients’ subset than in the low IL-13 patient’s subset. Taken together data suggest that UC 
patients showing high IL-13 mRNA tissue content have a more severe colitis than patients with low IL-
13 mRNA tissue content. This finding somehow differs from the observation reported in a treatment-
naive UC pediatric patients cohort characterized by concomitant increased mucosal IL-17A and IL-13 
mRNA (41). In this cohort of patients, higher IL-13 expression was associated significantly with an 
increased likelihood of clinical response at 6 and 12 months to first-line therapies (i.e. corticosteroids, 
mesalamine, and thiopurines) and steroid free remission compared with that of patients characterized 
by essentially undetectable IL-13 expression. Moreover, during the same period of time, these patients 
were less exposed to anti-TNF-biologic drugs. In our cohort, patients with high and low IL-13 mRNA 
did not differ in the clinical response or in the percentage of patients experiencing a clinical relapse 
during the one year follow-up, however the use of systemic corticosteroids, immunosuppressant and 
anti-TNF-α biologic drugs was higher in the high IL-13 mRNA patient subset. It is quite possible that 
in newly diagnosed pediatric patients in which the immune-response is not influenced by the effects of 
inflammatory relapses and consequent therapy, initial induction of IL-13 is adequately counteracted by 
the standard therapy. Alternatively, increased production of IL-13 might even have, in the initial phase 
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of the disease, a protective role, as shown in some animal models (47- 49). However, with the progression 
of the disease, inflammatory flares and their treatment might induce changes favoring the occurrence or 
amplification, in genetically predisposed individuals, of autoimmunity phenomena as trigger of IL-13 
production that switch the role of IL-13 production from protective to pathogenic. Indeed, in adult UC 
patients, it has been recently demonstrated the presence in colonic lamina propria of increased 
proportion of NKT cells able to produce IL-13 in response to lysosulfatide, a sulfatide glycolipid (50). 
Sulfatide glycolipids are self-antigens present in cells in many tissues including the epithelial cells in 
the gastrointestinal tract. A stress response of genetically conditioned epithelial cells to certain type of 
bacteria in the colonic microbiota may indeed promote the autoimmune-induced IL-13 production. 
 Interesting, in the present study, we observed different mucosal microbial profiles associated to the 
two patients’ subsets. Particularly, while mucosa-associated microbiota in patients with high IL-17A 
and low IL-13mRNA is enriched in Sutterella and Acidaminococcus, Prevotella (mainly Prevotella 
copri) is enriched in the mucosa-microbiota of patients showing increased IL-13 mRNA content in 
addition to high IL-17A mRNA content. It is worth to note that Sutterella (51), Acidaminococcus (52) and 
Prevotella copri (53) have been reported to be increased in fecal microbiota of UC patients. All of these 
microorganisms are classically considered commensal bacteria due to their extensive presence in the 
healthy human body. However, emerging studies have linked increased Prevotella abundance and 
specific strains to inflammatory disorders, suggesting that at least some strains exhibit pathobiontic 
properties. In particular, it has been recently reported that expansion of Prevotella copri in fecal 
samples strongly correlate with disease in new-onset untreated patients with rheumatoid arthritis, a 
systemic autoimmune disease (54). In the same study it has been described its ability, after colonization 
of mice, to increase sensitivity to chemically induced colitis (54). Indeed Prevotella might disrupt the 
mucosal barrier function through production of sulfatases that actively degrade mucus oligosaccharides 
(55). Thus, it is plausible that the dysbiotic community observed in the high IL-13 mRNA patients 
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subsets (enriched in Prevotella genus), might influence the epithelial stress response, favoring the 
presentation of autoantigens contributing to the pathogenic role of IL-13. On the other hand, the 
microbial community enriched in both Sutterella and Acidaminococcus, characterizing the low IL-13 
mRNA subset of patients, might contribute to a less severe disease. In fact, although Sutterella was 
described to be associated with lack of remission after fecal microbiota transplantation (56), recent 
studies, showed the ability of Acidaminococcus genus to produce short chain fatty acids (57). Short 
chain fatty acids are in fact considered important metabolites as they serve as the major energy source 
for colonocytes, they have anti-inflammatory properties and regulate gene expression, in host cells (58). 
The existence of the two subsets of patients observed in the present study introduces some issues about 
the clinical implications of the finding. It is presently unknown whether the two subsets of patients are 
such since the onset of the disease or if they represent different stages of the disease. Very recently, it 
has been reported, in 15 patients with active ulcerative, that mucosal immune profiles differ during 
early and late phases of the disease, with a Th1 and Th2-driven prevalent profile disease in early and 
late disease, respectively (59). However, in the study, IL-13 expression in paired samples from early and 
late disease has not been evaluated. Patients evaluated in the present study have, at the time of 
endoscopy, a median time of 9 years of disease duration from the diagnosis thus belonging, according 
to the above-reported study, to the “late disease”. However, we did not observe differences in the 
disease duration between the two patients’ subsets, yet the age at diagnosis was significantly lower in 
patients with high IL-13 and these same patients showed more frequently an extended colitis, similar to 
the observations reported in pediatric patients (41). Therefore, we favor the view about the existence of 
subsets of UC patients showing different IL-13mRNA content from the onset of the disease.  
The different cytokine profile might be differentially associated to the presence of different serological 
markers and to their prognostic ability (60, 61), so that it might be useful to combine the assessment of 
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tissue cytokine profile with the assessment of serological markers to obtain an increased prognostic 
ability.  
Finally, the findings described in the present study might have important implications on therapeutic 
strategies in UC. The observation that IL-6, TNF-, IFN- and IL-10 mRNA tissue content were each 
other strongly correlated, while IL-17A and IL-13 variations were both independent from all the other 
cytokines and independent of each other suggests that IL-17A and IL-13 mRNA contents are 
distinctive features of the pathogenic process of UC. As that, therapy oriented to the neutralization of 
inflammatory cytokines might only indirectly and differentially affect the IL-17A and IL-13 expression 
which in turn might influence the response to the neutralization of inflammatory cytokines. Notably, it 
has been shown that response to infliximab treatment was significantly associated with higher 
pretreatment mucosal IL-17A gene expression (62), and fewer Gata3+ T cells were observed in the 
lamina propria of anti-TNF-α responders, than in non-responders patients (63). Beyond these 
considerations, an important therapeutic implication of the findings reported in the present study 
concerns the treatment of patients with high IL-13 mRNA tissue content. As recently highlighted (64, 65) 
previous results obtained with IL-13 neutralizing treatments might be reconsidered according to the IL-
13mRNA colonic content of the patients that have been studied. A treatment approach that specifically 
target IL-13 or a different IL-13 receptor (66) might indeed be effective in the patients’ subset with high 
IL-13mRNA tissue content identified in this study.  
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FIGURE LEGEND 
 
Figure 1: Cytokine mRNA tissue content in controls samples (n=20), in the uninvolved tissue (n=50) 
and involved tissue (n=77) of UC patients. Lines represent median and range. p= as for Mann-Whitney 
test. 
Figure 2: Mean values location in the bi-dimensional IL-17A vs IL-13 plane is different in UC (n=77) 
and Controls (n=20). Data in a bivariate mean/SE plane for both IL-13 and IL-17A. Points represents 
mean±SE. 
Figure 3: UC patients are distributed in six clusters characterized by high and low IL-13 mRNA and 
increased IL-17A mRNA tissue content. Panel A: Data distribution of subjects (UC patients and 
controls) in the IL-17A/IL-13 plane. Each point represent patient or control IL-17A/IL-13 mRNA 
values. Lines represent mean of IL-17A and IL-13. Panel B: Distribution of clusters in the IL-17A/IL-
13 plane. Each point represent patient or control IL-17A/IL-13 mRNA values- associated cluster. Panel 
A and B: UC patients   n=77; Controls  n=20 
 
Figure 4: Clusters in the IL-13/IL-17A plane show differences as for sex (A), age at diagnosis (B), 
prevalence of extensive colitis (C) and steroid/ immunosuppressant/biological therapy use (D).  Panel 
A, B, and C: UC patients n=77. Panel D: UC patients n=42. 
Figure 5: Explorative analyses and comparison of mucosal associated microbiota composition in UC 
and control subjects. (A) Barplot shows the composition at the Family level, according with the 
Phylum of belonging. Family with relative abundance < 1% were discarded. (B) PCoA ordination 
based on Bray-Curtis dissimilarities of mucosal samples from UC (involved, n=79, and uninvolved, 
n=57, tissue) and controls (n=21). PERMANOVA using the Adonis function with 999 permutations 
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resulted not significant. (C-D) LEfSe analysis showing significantly biomarker taxa in two different 
comparisons, based on (C) disease status: UC (both involved and uninvolved tissue, passed as 
subclasses t LEfSe) compared to control samples, and (D) tissue: controls versus uninvolved versus 
involved tissue in UC patients. Cladograms show the most discriminative bacterial clades. Coloured 
regions/branches indicate differences in the bacterial population structure between the different groups. 
Statistically significant taxa enrichment among groups was obtained with Kruskal-Wallis test among 
classes (Alpha value = 0.05). The threshold for the logarithmic LDA score was 2.0. 
Figure 6. Comparison of mucosal microbial profiles between UC patients belonging to Cluster 2 (CL2, 
n = 10) and Cluster 6 (CL6, n = 30). LEfSe analysis showing significantly enriched biomarker taxa in 
CL6 vs CL2 comparisons. Cladogram and barplot show the most discriminative bacterial clades. 
Colored regions/branches indicate differences in the bacterial population structure between the 
different CL2 and CL6. Statistically significant taxa enrichment among groups was obtained with 
Kruskal-Wallis test among classes (Alpha value = 0.05). The threshold for the logarithmic LDA score 
was 2.0. 
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Table 1. Clinical-pathological variables of patients at time of endoscopy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 Ulcerative Colitis 
n. 
77 
Controls 
n. 
20 
Age at the time of endoscopy 
years: median (range) 
51 (19-82) 57 (37-86) 
Gender M/F 
(n)/(n) 
45/32 10/10 
Disease Duration from diagnosis 
years: median (range) 
9 (0-36)  
 
 
Endoscopic Activity 
(Mayo Score) 
median (range) 
2 (1-3) 
Disease Extension  
Proctitis 29 
Left Sided Colitis 29 
Extensive Colitis 19 
Therapy  
CS 2+ 10* 
5-ASA agents 50+ 23* 
Immune modulators 1+10* 
Biological Agents 2* 
No therapy 4 
*Patients with combined therapy 
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Figure 1 
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Figure 2 
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Figure 3 
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Figure 4 
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Figure 5 
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Figure 6 
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